A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

NCT03583944 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Eribulin Mesylate

Sponsor

Eisai Inc.